CXCL12 and neoplasm: Müller et al demonstrated that anti-EGFRvIII CAR-NK cells modified to produce CXCR4 conferred selective chemotaxis to CXCL12/SDF1-secreting glioblastoma cells in a mouse model of glioblastoma, leading to better tumor regression and survival (149).